Back to Stocks

SRZN

Surrozen, Inc./DE
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Surrozen is successfully transitioning from a speculative research entity to a milestone-validated biotechnology platform.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic narrative, Surrozen's financial health is precariously tied to a single binary regulatory event.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every SRZN filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company at a critical crossroads, where technical validation is clashing with financial volatility. The receipt of the Boehringer Ingelheim milestone payment proves that Surrozen's Wnt-modulating platform has commercial utility, but the massive non-cash losses highlight the complex and risky nature of its financing structures. The company has effectively traded long-term stability for a high-stakes binary outcome centered on the SZN-8141 IND filing. Investors are now faced with a clear trade-off: the potential for a massive value inflection point upon FDA clearance versus the risk of a liquidity crisis should that clearance be delayed. While the current cash position provides a 12-month cushion, the structural dependence on the contingent PIPE tranche means that the company's valuation is now inextricably linked to regulatory timelines rather than just scientific merit. Ultimately, the filing suggests that Surrozen is executing its scientific roadmap effectively, but its financial architecture remains aggressive. The next six months will be decisive, as the market watches for the SZN-8141 IND submission and the subsequent unlocking of nearly $100 million in capital.

Selected Quarter

Core Takeaway

Surrozen has validated its platform via a major partner milestone but remains financially dependent on a binary FDA event to unlock $95.1M in funding.

Investor Lens

The trade-off between the validated scientific platform and the high-risk, binary nature of the current capital structure.

Watch Next

FDA clearance of the SZN-8141 IND application expected in H2 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.17Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 6

Reported a net loss of $127.5 million driven by non-cash liability adjustments.

earnings miss
70%
bullishMay 6

Raised $26.9 million through an ATM program during the quarter.

capital raise
60%
bearishMay 6

R&D expenses increased 42% year-over-year to $9.3 million.

margin compression
40%
bearishMay 6

Reported a net loss of $127.5 million driven by non-cash liability adjustments.

earnings miss
70%
bullishMay 6

Raised $26.9 million through an ATM program during the quarter.

capital raise
60%
bearishMay 6

R&D expenses increased 42% year-over-year to $9.3 million.

margin compression
40%
bearishMay 6

Reported a net loss of $127.5 million driven by non-cash liability adjustments.

earnings miss
70%
bullishMay 6

Raised $26.9 million through an ATM program during the quarter.

capital raise
60%
bearishMay 6

R&D expenses increased 42% year-over-year to $9.3 million.

margin compression
40%
bearishMay 6

Reported a net loss of $127.5 million driven by non-cash liability adjustments.

earnings miss
70%
bullishMay 6

Raised $26.9 million through an ATM program during the quarter.

capital raise
60%
bearishMay 6

R&D expenses increased 42% year-over-year to $9.3 million.

margin compression
40%
bearishMay 6

Reported a net loss of $127.5 million driven by non-cash liability adjustments.

earnings miss
70%
bullishMay 6

Raised $26.9 million through an ATM program during the quarter.

capital raise
60%
bearishMay 6

R&D expenses increased 42% year-over-year to $9.3 million.

margin compression
40%
bearishMay 6

Reported a net loss of $127.5 million driven by non-cash liability adjustments.

earnings miss
70%
bullishMay 6

Raised $26.9 million through an ATM program during the quarter.

capital raise
60%
bearishMay 6

R&D expenses increased 42% year-over-year to $9.3 million.

margin compression
40%
bearishMay 6

Reported a net loss of $127.5 million driven by non-cash liability adjustments.

earnings miss
70%
bullishMay 6

Raised $26.9 million through an ATM program during the quarter.

capital raise
60%
bearishMay 6

R&D expenses increased 42% year-over-year to $9.3 million.

margin compression
40%

Filing History

10-QMay 6, 2026
Expand Sequence

The Q1 2026 filing reveals a company at a critical crossroads, where technical validation is clashing with financial volatility. The receipt of the Boehringer Ingelheim milestone payment proves that Surrozen's Wnt-modulating platform has commercial utility, but the massive non-cash losses highlight the complex and risky nature of its financing structures. The company has effectively traded long-term stability for a high-stakes binary outcome centered on the SZN-8141 IND filing. Investors are now faced with a clear trade-off: the potential for a massive value inflection point upon FDA clearance versus the risk of a liquidity crisis should that clearance be delayed. While the current cash position provides a 12-month cushion, the structural dependence on the contingent PIPE tranche means that the company's valuation is now inextricably linked to regulatory timelines rather than just scientific merit. Ultimately, the filing suggests that Surrozen is executing its scientific roadmap effectively, but its financial architecture remains aggressive. The next six months will be decisive, as the market watches for the SZN-8141 IND submission and the subsequent unlocking of nearly $100 million in capital.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.